NEW YORK, NY -- (Marketwire) -- 10/21/11 -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cardium Therapeutics, Inc. (NYSE Amex: CXM) and Oncothyreon, Inc. (NASDAQ: ONTY). Access to the full company reports can be found at:
www.paragonreport.com/CXM
www.paragonreport.com/ONTY
While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Oncothyreon recently announced enrolment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. According to Oncothyreon, "PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway."
Cardium Therapeutics, Inc. is a development-stage company. Cardium's business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. The company plans to initiate the Aspire Generx Clinical Study for patients with advanced coronary artery disease at major medical centers in Russia in connection with commercialization plans covering the marketing and sale of Generx in the Russian Federation.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
